Amgen (FRA:AMG) Tariff Resilience Score: 7/10 (As of Jul. 05, 2026)


FRA:AMG Amgen Inc FRA:AMG
88 GF Score
Price €326.65
GF Value €308.79
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Amgen Tariff Resilience Score?

Amgen FRA:AMG +2.08% 88 Tariff Resilience Score is 7 as of Jul. 05, 2026. GuruFocus rates FRA:AMG with a GF Score™ of 88/100 and a GF Value™ of €308.79 (Fairly Valued). The stock has 9 warning signs investors should review. Among 1,028 Drug Manufacturers companies, Amgen ranks better than 97.08% on this metric.

Amgen has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Amgen has Amgen's global pharmaceutical operations face moderate tariff exposure, primarily on raw materials. The company has managed past impacts through strategic sourcing and pricing power. Industry-specific exemptions provide some protection, enhancing resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Amgen might have Highly Resilient.

Amgen  (FRA:AMG) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Amgen Tariff Resilience Score Related Terms

FRA:AMG vs GILD, PFE, BMY: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, Amgen's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Amgen's Tariff Resilience Score falls into.


FRA:AMG
88GF Score
Amgen Inc FRA:AMG
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Amgen (FRA:AMG) has a Tariff Resilience Score of 7 as of Jul. 05, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Amgen ranks #30 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Amgen's Tariff Resilience Score too high?
Amgen's current Tariff Resilience Score is 7. Based on the distribution chart, Amgen ranks #30 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amgen has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Tariff Resilience Score compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #30 out of 1028 companies for Tariff Resilience Score. This places Amgen in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Amgen's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (FRA:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €308.79, compared to a current price of €326.65 — trading 5.8% above its estimated fair value. The current Tariff Resilience Score is 7. Amgen's overall GF Score™ is 88/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Amgen (FRA:AMG), the current Tariff Resilience Score is 7 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (FRA:AMG) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of €326.65 is trading 5.8% above its estimated GF Value™ of €308.79. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for FRA:AMG:

  • Tariff Resilience Score: 7
  • GF Value™: €308.79 vs. price of €326.65 (5.8% above fair value)
  • GF Score™: 88/100 with 9 warning signs

No single metric tells the full story. See the FRA:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
88GF Score

Get the complete analysis for FRA:AMG

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€326.65
Price
€308.79
GF Value